News

News Subscription

Apr 21. 2017
Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections
Read more
Download
Apr 06. 2017
Data presented at AACR meeting indicate diverse tumor-targeting properties of Basilea's BAL101553 and show a combination potential with bevacizumab
Read more
Download
Feb 27. 2017
Basilea proposes Dr. Nicole Onetto as new member of the Board of Directors
Read more
Download
Feb 20. 2017
Basilea reports solid 2016 results and expects to double product sales in 2017
Read more
Download
Dec 29. 2016
Basilea names new member of its Extended Management Committee
Read more
Download
Dec 02. 2016
Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients
Read more
Download
Nov 15. 2016
Basilea's antifungal Cresemba® (isavuconazole) launched in France
Read more
Download
Sep 20. 2016
Basilea announces distribution agreement with Unimedic for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in the Nordic countries
Read more
Download
Sep 15. 2016
Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma
Read more
Download
Sep 13. 2016
Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in Latin America
Read more
Download